Adenosquamous carcinoma (ASC) of the esophagus is an uncommon type of esophageal cancer that contains both adenocarcinoma and squamous cell carcinoma elements. Data on this biologically unique type of cancer are limited and mainly stem from case reports and small case series. We performed an audit of the available literature and synthesized a review on the epidemiology, pathogenesis, histopathology, clinical manifestations, diagnosis, treatment and prognosis of ASCs. Adenosquamous carcinoma of the esophagus is a rare type of esophageal cancer. Histological examination is necessary to confirm the diagnosis of ASC and patients usually receive multimodal treatment. Patient outcomes are not well defined and further research could help us better understand the pathophysiology and unique needs of patients with this rare malignancy.

Key words: adenosquamous carcinoma, esophageal cancer, esophageal carcinoma, esophageal tumor, esophageal malignancy

INTRODUCTION

Esophageal cancer is the 8th most common type of cancer worldwide and the 6th leading cause of cancer-related deaths. The two major histological types of esophageal cancer are Squamous Cell Carcinoma (SCC) and Adenocarcinoma (AC). There are significant geographic variations in the incidence rates of esophageal cancer and its histological types. SCC is the most prevalent esophageal cancer worldwide, while AC occurs more frequently in Western countries.[1,2] One of the less common variants of esophageal cancer is Adenosquamous Carcinoma (ASC), which is comprised by both SCC and AC elements. Literature on ASC is scarce and mostly consists of small case series.[3–7] Only recently did larger case series emerge.[8,9] The purpose of this review is to summarize the existing data on epidemiology, pathogenesis, histopathology, clinical characteristics, diagnosis and staging of ASC, as well as treatment and prognosis.
Based on the aforementioned classification systems, there are two ways to define ASC. According to the Japan Esophageal Society (JES), in order for an esophageal tumor to be characterized as ASC, the SCC component and AC component need to be identified under microscopic examination, with each accounting for at least 20% of the tumor. On the other hand, the WHO Classification of Digestive Tumors states that ASC is any esophageal lesion containing a significant SCC component intermingled with tubular AC elements, with no special reference to the ratio of these two components.

**EPIDEMIOLOGY**

ASC is a rare type of esophageal cancer. In patient series from both Asia and the US, the reported incidence rates range between 0.37% and 1%. The age and gender distribution is also consistent throughout the literature. ASC mostly presents in people older than 40 years, with incidence peaking around the 7th decade of life. Men are more frequently affected than women, with male-to-female ratios ranging from 4:1 to 8:1.

**PATHOGENESIS**

The origin of ASC is not clear yet and various theories regarding the histogenesis of these tumors have been suggested. Several authors have studied ASC in the setting of Barrett’s Esophagus. Pascal et al. suggested that ASC arises from esophageal gland cells or ductal cells. Because epithelium and submucosal glands are all derived from the foregut during embryogenesis, the AC component has the potential to transform into SCC. In addition, Van Rees et al. proposed a tumor progression pathway in which Barrett’s epithelium, after losing hetrozygosity at chromosome arm 9p, exhibits further loss of hetrozygosity at several other chromosomal loci and a missense mutation in the p53 gene. From there, a malignant cell can develop into either SCC or AC. If an additional shift at chromosomal arm 16q occurs, AC can develop. In contrast, some authors believe that ASC arises from the mucosa, where it begins originally as SCC and glandular differentiation occurs later within the tumor. Last but not least, a collision concept has been proposed, in which ASC comes from two individual stem cells that simultaneously and independently undergo malignant transformation.

**HISTOPATHOLOGY**

ASC has various macroscopic tumor types, such as ulcerative, medullary, intraluminal, polypoid and sclerotic, and upon macroscopic inspection, it is indistinguishable from SCC. Microscopically, it is characterized by an AC and a SCC component that either have a clear boundary or exhibit a gradual transition between them. This is a main point of differentiation with Mucoepidermoid Carcinoma of the Esophagus (MECE), where the mixture of squamous cells and mucus secreting cells is homologous and intermediate cells can be observed. The SCC element contains pathologic findings such as keratin pearl formation, zonal differentiation towards the center of the tumor nests and intercellular bridges, while the AC element is characterized by the presence of tubular and/or glandular structures and, occasionally, by mucus production. Finally, both Chen and Yachida found that the squamous cell component dominates in the mucosa and the AC component is mainly found in the deeper parts of the tumor.

**CLINICAL PRESENTATION**

ASC has shown clinical manifestations with SCC and AC. Studies have shown dysphagia to be the most common presenting symptom of ASC, followed by retrosternal or upper abdominal pain and weight loss. There are discordant reports throughout the literature regarding the location distribution of ASC. In some studies, ASC mainly presented in the middle esophagus, which is the area where SCC is most commonly found. In contrast, others reported the distal esophagus as being more frequently affected, thus resembling the distribution pattern of AC.

**DIAGNOSIS**

Even though esophagogastroduodenoscopy (EGD) with endoscopic biopsy is important in the preoperative diagnosis of esophageal cancer; when it comes to ASC, it has been shown to have low diagnostic accuracy. Large series have reported a misdiagnosis rate of 61.1%–100%, and in most cases, that diagnosis was SCC. Only when resection specimens from surgery were examined, the tumors were found to be ASC. A reason for this discrepancy could be the fact that, in most tumors, the SCC component is located in the mucosa, while the AC component is mainly found in deeper areas of the tumor, where getting specimen from is not always possible.

**STAGING**

Throughout literature, the AJCC/UICC TNM staging system has been utilized in the staging of ASC. The predominant stage at the time of diagnosis differed between the studies. In the same way, the data regarding the distribution of patients in different pT and pN stages are contradicting. When it comes to Tumor Grade, several
studies showed that ASC are more commonly higher grade tumors (poorly differentiated or undifferentiated) than lower grade.[3,5,9] Finally, Yendamuri et al.[9] found that ASC is at more advanced stages and higher grade when diagnosed, in comparison with AC and SCC.

TREATMENT

The role of surgery and other therapeutic measures on the treatment of ASC are yet unclear. Current literature is limited to patient treatment allocation statistics and observational data regarding prognosis. The two largest patient series to date have found that approximately 33–37% of patients with ASC underwent surgical removal of the tumor. When compared with the other histological types, ASC and AC had comparable resection rates and both were more frequently resected than SCC. These studies also reported that approximately 55% received Radiation Therapy, the same as in AC, but lower than SCC. Evans et al. also showed that 60% of ASC patients received Chemotherapy, a rate similar to the other histological types. A major limitation of those studies is that they do not specify if those non-surgical modalities are neo-adjuvant or adjuvant.[8,9]

The treatment of esophageal cancer is multimodal. Surgical resection is the cornerstone of treatment for locally advanced SCC and AC. No approach has been found to be superior over others in regard to survival and the choice of surgical technique mainly depends on the tumor location and the preference of the surgeon. In addition, lymph node dissection and adequate lymph node sampling are important parts of surgery, although the extent of lymphadenectomy (two-field vs. three-field lymphadenectomy) is still a matter of debate.[11] Provided that the tumor is resectable and not misdiagnosed as another type, it would be safe to assume that the principles mentioned for SCC and AC are applicable to ASC.

What is more, non-surgical therapeutic measures, such as radiotherapy and chemotherapy, play a significant part in the treatment of esophageal cancer. The combination and timing of those treatments are matters of great complexity. Nevertheless, it seems that neoadjuvant therapy, either chemoradiotherapy or chemotherapy, offers a significant survival advantage over surgery alone in both major histological types.[25] As a result, the adoption of neoadjuvant modalities seems like the reasonable choice when it comes to ASC. Finally, since the role of adjuvant therapy differs between SCC and AC, no logical conclusion for the use in ASC can be drawn.

PROGNOSIS

Current literature is conflicting when it comes to the prognosis of ASC. The reported Median Survival Time (MST) is 9.6–44.4 months[3,5,6,8] and 5-year Overall Survival (OS) rates reported were as low as 12.8%[8] and as high as 63.6%.[7]

Although the relationship between various clinicopathological features of ASC and prognosis has been examined by most authors, no consensus has been reached yet on what the prognostic factors of ASC are. In univariate analyses, each author found a different set of variables that significantly affected survival.[3–6,9] In multivariate analyses, Ni et al. and Zhang et al. reported lymph node metastasis to be the only independent prognostic factor for ASC, while Chen et al. found that only adjuvant radiotherapy independently affected survival. Finally, in a study by Sun et al., the independent prognostic factors were tumor length, perineural invasion and the type of surgical resection.[3–6]

When the survival of ASC was compared with AC and SCC, the results were also contradictory. The largest patient series was by Evans et al., where ASC was found to have the same Median Survival Time (MST) with SCC and lower than AC. In the same study, the Overall Survival of ASC was lower than SCC and AC.[10] In contrast, Chen et al. reported that ASC has lower MST and OS than SCC.[9] Finally, Yachida et al. shows that the OS for ASC is better than AC and SCC, but this finding can be attributed to the smaller size and lower stage of the ASC tumors in their study.[7]

CONCLUSION

In conclusion, adenosquamous carcinoma is a rare type of esophageal tumor that is challenging to diagnose prior to surgery. Potential solutions to maximize diagnostic accuracy could be deeper biopsies, that obtain a greater tissue sample, and stricter implementation of the JES and WHO diagnostic criteria. Patients with these tumors may benefit from a multidisciplinary treatment approach. However, definitive conclusions regarding pathogenesis, biological behavior, treatment and prognosis have yet to be reached. Therefore, future studies providing more granular data are required.

Conflict of Interest

The authors declare no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
REFERENCES

1. Pennathur A, Gibson MK, Jobe BA, Lakerich JD. Oesophageal carcinoma. Lancet 2013; 381: 400-2.
2. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics. 2012. CA Cancer J Clin 2015; 65: 87-108.
3. Ni PZ, Yang YS, Hu WP, Wang WP, Yuan Y, Chen LQ. Primary adenosquamous carcinoma of the esophagus: an analysis of 39 cases. J Thorac Dis 2016; 8: 2689-96.
4. Sun YH, Lin SW, Chen CH, Liang W, Hsieh CC. Adenosquamous Carcinoma of the Esophagus and Esophagogastric Junction: Clinical Manifestations and Treatment Outcomes. J Gastrointest Surg 2015; 19: 1216-22.
5. Zhang HD, Chen CG, Gao YY, Ma Z, Tang P, Duan XF, et al. Primary esophageal adenosquamous carcinoma: a retrospective analysis of 24 cases. Dis Esophagus 2014; 27: 783-9.
6. Chen SB, Weng HR, Wang G, Yang JS, Yang WP, Liu DT, et al. Primary adenosquamous carcinoma of the esophagus. World J Gastroenterol 2013; 19: 8382-90.
7. Yachida S, Nakanishi Y, Shimoda T, Nimura S, Igaki H, Tachimori Y, et al. Adenosquamous carcinoma of the esophagus. Clinicopathologic study of 18 cases. Oncology 2004; 66: 218-25.
8. Evans M, Liu Y, Chen C, Steuer C, Cassidy III R, Landry J, et al. Adenosquamous Carcinoma of the Esophagus: An NCDB-Based Investigation on Comparative Features and Overall Survival in a Rare Tumor. Oncology 2017; 93: 519-21.
9. McPeak E, Arons WL. Adenoacanthoma of the esophagus; a report of one case with consideration of the tumor’s resemblance to so-called salivary gland tumor. Arch Pathol 1947; 44: 385-90.
10. Pasic RR, Clearfield HR. Mucoepidermoid (adenosquamous) carcinoma arising in Barrett’s esophagus. Dig Dis Sci 1987; 32: 428-32.
11. Japan Esophageal Society. Japanese Classification of Esophageal Cancer, 11th Edition: part II and III. Esophagus 2016; 14: 37-65.
12. Flejou JF. WHO Classification of digestive tumors: the fourth edition (in French). Ann Pathol 2011; 31 Suppl: S27–S31
13. Noguchi T, Uchida Y, Fumoto S, Wada S, Sato T, Takeno S. Adenosquamous carcinoma arising in Barrett’s esophagus. Jpn J Thorac Cardiovasc Surg 2002; 50: 537-40.
14. van Rees BP, Rouse RW, de Wit MJ, van Noesel CJ, Tytgat GN, van Lanschot JJ, et al. Molecular evidence for the same clonal origin of both components of an adenosquamous Barrett carcinoma. Gastroenterology 2002; 122: 784-8.
15. Ter RB, Gowił YK, Leite I, Infantolino A, Ghabra M, Galan A, et al. Adenosquamous carcinoma in Barrett’s esophagus presenting as pseudocachexia. Am J Gastroenterol 1999; 94: 268-70.
16. Streppel MM, Siersema PD, de Leng WW, Morsink FH, Vleggaar FP, Maitra A, et al. Squamous cell carcinoma in Barrett’s esophagus: field effect versus metastasis. Dis Esophagus 2012; 25: 630-7.
17. Zhao S, Xue Q, Ye B, Lu H, He J, Zhao H. Synchronous primary carcinomas and adenosquamous carcinoma of the esophagus. Ann Thorac Surg 2011; 91: 926-8.
18. Bombi JA, Riverola A, Bordas JM, Cardesa A. Adenosquamous carcinoma of the esophagus. A case report. Pathol Res Pract 1991; 187: 514-9; discussion 519-21.
19. Resano CH, Cabrera N, Gonzalez Cueto D, Sanchez Basso AE, Rubio HH. Double early epidermoid carcinoma of the esophagus in columnar epithelium. Endoscopy 1985; 17: 73-5.
20. Sakata K, Ishida M, Hiraishi H, Sasaki T, Watanabe N, Suzuki Y, et al. Adenosquamous carcinoma of the esophagus after endoscopic variceal sclerotherapy: a case report and review of the literature. Gastrointest Endosc 1998; 47: 294-9.
21. Epstein JJ, Sears DL, Tucker RS, Egan JW Jr. Carcinoma of the esophagus with adenoid cystic differentiation. Cancer 1984; 53: 1131-6.
22. Lam KY, Loke SL, Ma LT. Histochemistry of mucin secreting components in mucoepidermoid and adenosquamous carcinoma of the oesophagus. J Clin Pathol 1993; 46: 1011-5.
23. Huang Q, Shi J, Sun Q, Fan X, Feng A, Wu H, et al. Distal esophageal carcinomas in Chinese patients vary widely in histopathology, but adenocarcinomas remain rare. Hum Pathol 2012; 43: 2138-48.
24. Rustgi AK, El-Serag HB. Esophageal Carcinoma. N Engl J Med 2014; 371: 2499-509.
25. Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction. Ann Surg Oncol 2010; 17: 1721-4.

How to cite this article: Schizas D, Kapsampelis P, Mylonas KS. Adenosquamous carcinoma of the esophagus: A literature review. J Transl Intern Med 2018; 6: 70-3.